Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib study aims to assess the safety and feasibility of combination of chimeric
receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion
of study population in HER2+ metastatic breast cancer once safety has been established.